{"id":797,"date":"2026-10-19T21:12:38","date_gmt":"2026-10-20T01:12:38","guid":{"rendered":"http:\/\/novameds.local\/ca\/?post_type=product&#038;p=797"},"modified":"2026-10-19T21:58:21","modified_gmt":"2026-10-20T01:58:21","slug":"catalog-myostatin-1mg","status":"publish","type":"product","link":"https:\/\/novameds.health\/ca\/product\/catalog-myostatin-1mg\/","title":{"rendered":"Myostatin 1mg"},"content":{"rendered":"<section id=\"composition\" data-nav=\"Composition and product details\">\n<h2>Composition and product details<\/h2>\n<div class=\"nm-catalog-document\">\n<div>\n<h2>Overview<\/h2>\n<div>\n<p>MIP-7 (Myostatin Inhibitory Peptide 7) is a synthetic 24-amino-acid, C-terminally amidated peptide (AWRQNTRYSRIEAIKIQILSKLRL-NH2) derived from the N-terminal \u03b1-helical region of the mouse myostatin prodomain. In the native latent complex, this region of the prodomain helps hold mature myostatin (GDF-8) in an inactive state.<\/p>\n<p>MIP-7 was developed to reproduce that inhibitory interaction in a short, synthetically accessible sequence. It is not myostatin itself and does not activate the myostatin pathway. It is studied as a myostatin antagonist, binding the mature growth factor and reducing its ability to signal through activin type II receptors (ACVR2A\/ACVR2B) and downstream Smad2\/3.<\/p>\n<p>Research applications include myostatin inhibition studies, prodomain\u2013ligand interaction research, structure\u2013activity work on peptide-based TGF-\u03b2 superfamily antagonists, and muscle biology models where myostatin signalling is suppressed.<\/p>\n<ul>\n<li> <span><b>High Purity<\/b> \u2013 99% Purity Guaranteed<\/span><\/li>\n<li> Independently Lab Tested<\/li>\n<li> Research Grade Quality<\/li>\n<li> For Laboratory Research Use Only<\/li>\n<\/ul><\/div>\n<div>\n<p><a href=\"https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/118732224\" target=\"_blank\" rel=\"noopener noreferrer\">Molecular data on PubChem<\/a><\/p>\n<div>\n<div><span>Myostatin 1mg<\/span><span>1 vial | KIT (10 vials)<\/span><\/div>\n<\/div><\/div>\n<\/p><\/div>\n<div>\n<h2>Properties<\/h2>\n<div class=\"nm-catalog-table\" tabindex=\"0\" role=\"region\" aria-label=\"Product data\">\n<table>\n<tbody>\n<tr>\n<th>Chemical Formula<\/th>\n<td>C133H227N43O33<\/td>\n<\/tr>\n<tr>\n<th>Synonyms<\/th>\n<td>1621169-52-5, Myostatin inhibitory peptide 7, U8DGS69FVC Ala-Trp-Arg-Gln-Asn-Thr-Arg-Tyr-Ser-Arg-Ile-Glu-Ala-Ile-Lys-Ile-Gln-Ile-Leu-Ser-Lys-Leu-Arg-Leu-NH2, UNII-U8DGS69FVC, CHEMBL3410227, L-Alanyl-L-tryptophyl-L-arginyl-L-glutaminyl-L-asparaginyl-L-threonyl-L-arginyl-L-tyrosyl-L-seryl-L-arginyl-L-isoleucyl-L-alpha-glutamyl-L-alanyl-L-isoleucyl-L-lysyl-L-isoleucyl-L-glutaminyl-L-isoleucyl-L-leucyl-L-seryl-L-lysyl-L-leucyl-L-arginyl-L-leucinamide, orb2563812<\/td>\n<\/tr>\n<tr>\n<th>Molar Mass<\/th>\n<td>2956.5 g\/mol<\/td>\n<\/tr>\n<tr>\n<th>CAS Number<\/th>\n<td>1621169-52-5<\/td>\n<\/tr>\n<tr>\n<th>PubChem CID<\/th>\n<td>118732224<\/td>\n<\/tr>\n<tr>\n<th>Available formats<\/th>\n<td>1 vial \u00b7 KIT (10 vials)<\/td>\n<\/tr>\n<tr>\n<th>Shelf Life<\/th>\n<td>24 months<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div><\/div>\n<div>\n<h2>Research<\/h2>\n<p>Myostatin (GDF-8) is a TGF-\u03b2 superfamily growth factor that negatively regulates skeletal muscle mass. It is synthesised as a precursor and held in a latent state by its own prodomain, which shields the receptor-binding surfaces of the mature dimer. Peptides derived from the prodomain therefore represent a direct route to myostatin inhibition.<\/p>\n<p>MIP-7 comes out of structure\u2013activity work by Takayama and colleagues (J Med Chem, 2015), which narrowed the mouse myostatin prodomain down to a minimum inhibitory sequence and then refined it. Follow-up structural studies indicate the peptide adopts an \u03b1-helical conformation and interacts with mature myostatin in a way that interferes with receptor engagement.<\/p>\n<p>MIP-7 is used in vitro to inhibit myostatin-induced Smad2\/3 signalling and reporter activity, typically alongside recombinant myostatin as the activating ligand. Additional applications include comparison against other myostatin inhibitors (follistatin, soluble ACVR2B, antibodies), investigation of prodomain-mediated latency, and design of next-generation peptide antagonists.<\/p>\n<p>Independently third-party HPLC-tested; COA available per batch.<\/p>\n<\/p><\/div>\n<div>\n<h2>FAQ<\/h2>\n<div>\n<details>\n<summary>\n\t\t\t\t\t\t\t\t\t\t<span>Is MIP-7 the same as myostatin (GDF-8)?<\/span><\/p>\n<\/summary>\n<div>\n<p>No. Myostatin (GDF-8) is a ~25 kDa homodimeric growth factor that activates the ACVR2B\/Smad2\/3 pathway. MIP-7 is a 24-residue synthetic peptide (2956.5 g\/mol) derived from the myostatin prodomain, and it is studied as an inhibitor of myostatin rather than an activator.<\/p>\n<\/div>\n<\/details>\n<details>\n<summary>\n\t\t\t\t\t\t\t\t\t\t<span>What is the primary research use of MIP-7?<\/span><\/p>\n<\/summary>\n<div>\n<p>MIP-7 is used to inhibit myostatin activity in experimental systems. A common design pairs recombinant myostatin (to activate Smad2\/3 signalling) with MIP-7 to measure how effectively the peptide suppresses that response, using reporter assays, Smad2\/3 phosphorylation or downstream transcriptional readouts.<\/p>\n<\/div>\n<\/details>\n<details>\n<summary>\n\t\t\t\t\t\t\t\t\t\t<span>What controls are important in MIP-7 experiments?<\/span><\/p>\n<\/summary>\n<div>\n<p>Common controls include vehicle-only samples for baseline, myostatin-only samples to confirm pathway activation, a scrambled or inactive peptide to rule out non-specific effects, and an established myostatin inhibitor (such as follistatin or a neutralising antibody) as a benchmark for inhibition.<\/p>\n<\/div>\n<\/details><\/div>\n<\/p><\/div>\n<\/div>\n<\/section>\n","protected":false},"excerpt":{"rendered":"<p>MIP-7 (Myostatin Inhibitory Peptide 7) is a synthetic 24-amino-acid, C-terminally amidated peptide (AWRQNTRYSRIEAIKIQILSKLRL-NH2) derived from the N-terminal \u03b1-helical region of the mouse myostatin prodomain.<\/p>\n<p>Presentation: Myostatin 1mg.<\/p>\n<p>Select the required strength and pack size.<\/p>\n<p class=\"nm-research-disclaimer\">For laboratory research only. Not for human or veterinary use.<\/p>\n<p class=\"nm-catalog-image-note\"><small>Illustrative packaging generated with AI.<\/small><\/p>\n","protected":false},"featured_media":973,"comment_status":"closed","ping_status":"closed","template":"","meta":[],"product_brand":[],"product_cat":[26],"product_tag":[],"nm_classification":[],"class_list":["post-797","product","type-product","status-publish","has-post-thumbnail","product_cat-recovery-regeneration","first","instock","shipping-taxable","purchasable","product-type-variable","has-default-attributes"],"_links":{"self":[{"href":"https:\/\/novameds.health\/ca\/wp-json\/wp\/v2\/product\/797","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/novameds.health\/ca\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/novameds.health\/ca\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/novameds.health\/ca\/wp-json\/wp\/v2\/comments?post=797"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/novameds.health\/ca\/wp-json\/wp\/v2\/media\/973"}],"wp:attachment":[{"href":"https:\/\/novameds.health\/ca\/wp-json\/wp\/v2\/media?parent=797"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/novameds.health\/ca\/wp-json\/wp\/v2\/product_brand?post=797"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/novameds.health\/ca\/wp-json\/wp\/v2\/product_cat?post=797"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/novameds.health\/ca\/wp-json\/wp\/v2\/product_tag?post=797"},{"taxonomy":"nm_classification","embeddable":true,"href":"https:\/\/novameds.health\/ca\/wp-json\/wp\/v2\/nm_classification?post=797"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}